Robotic-assisted Rehabilitation of the Extremities
Customize your policy alerts
Sign up for Aetna Policy 0778 alerts
Get alerted when Policy 0778 changes without checking for updates manually.
Monitor payer policy activity
This policy governs Aetna's coverage stance for robotic-assisted rehabilitation interventions and devices for upper and lower extremities, specifying which indications and devices are considered experimental/investigational and noting related policy cross-references. It affects providers submitting claims and prior authorization requests to Aetna.
No material clinical or coverage changes in this revision.
Coverage Criteria for Robotic-Assisted Rehabilitation
inv-01: Experimental and Investigational Indications
Not covered (experimental/investigational) for the following indications
List is not all-inclusive.
inv-02: Experimental and Investigational Devices
Devices/interventions considered experimental/investigational
List is not all-inclusive.
inv-03: Coverage criteria for electromechanical gait training
Covered when ALL of the following align with evidence from RCTs and systematic reviews
Based on planned subgroup and post-hoc analyses.
Trials combined RAGT with physiotherapy and showed increased odds of independent walking.
Heterogeneity of devices and protocols in trials noted; device-specific claims should reference supporting RCTs.
inv-04: Coverage criteria for robotic-assisted upper-limb training
Covered when ALL of the following align with evidence for upper-limb robotic training
Subgroup findings suggest better candidacy for those with residual function.
Pooled trials showed improved ADLs and arm function when matched for therapy dose; variability in protocols noted.
inv-05: Evidence summary and implications for coverage
Key clinical findings from trials and economic analyses relevant to coverage decisions:
Trial reported lack of functional benefit and unfavorable cost-effectiveness.
Impairment improvements noted but limited translation to ADL gains.
Evidence is mixed and condition-dependent.
Prototype/early clinical stage with heterogeneous reporting.
inv-06: Coverage considerations and evidence synthesis
Summary of evidence-based coverage considerations
Sources include pediatric RAGT reviews and BWSTT/RAGT vs over-ground systematic reviews.
Supported by recommendations to monitor individual progress and by studies showing potential adjunctive benefits in select populations.
Further high-quality trials are needed.
inv-07: Situations with evidence-supported benefit
Evidence suggests benefit under specific conditions:
Single-center trial (Tarnacka et al) showed greater MS and WISCI-II improvements in incomplete SCI with RAGT.
Meta-analysis (Zhang et al 2022) found small SMDs for FM-UE and activity post-intervention when total training time >15 hours; effects not sustained at follow-up.
Randomized trial reported maintained cfPWV improvement at 3 months.
inv-08: Evidence not supporting routine use
High-quality RCT evidence showing no superiority:
Higher serious adverse events were observed in robot and EULT arms though none attributable to the interventions.
The Myomo MyoPro myoelectric limb orthosis and similar myoelectric/robotic arm braces are classified in this policy as exercise equipment and are listed among devices considered experimental and investigational because their effectiveness for medical purposes has not been established. As noted, the Myomo MyoPro is regarded as exercise equipment by the FDA and most Aetna benefit plans exclude coverage for exercise equipment, so routine coverage should not be assumed.
Routine provision of body-weight–supported treadmill training (BWSTT) or robotic-assisted step training (RAST) in place of progressive, matched-intensity over‑ground training is discouraged outside of scientifically conducted efficacy trials. Systematic reviews and expert summaries conclude BWSTT/RAST have not consistently demonstrated superior outcomes compared with equivalent-dose progressive over‑ground training, and therefore should not replace conventional over‑ground therapy as a routine practice.
Economic analyses and a large multicenter trial indicate that some robotic-assisted interventions were unlikely to be cost‑effective at commonly used willingness‑to‑pay thresholds. Where an intervention lacks favorable cost‑effectiveness at standard WTP levels, payers may apply utilization management or limit coverage of that intervention unless strong, individualized clinical justification and outcome monitoring are documented.
The Intrepid Dynamic Exoskeletal Orthosis (IDEO) is a customized, energy‑storing ankle–foot orthosis developed for severe lower‑extremity injury, but current evidence is insufficient to support its generalized clinical value outside the structured integrated orthotic‑rehabilitation programs studied. Use of IDEO in routine civilian practice therefore remains experimental and investigational unless provided within defined protocols with prospective outcome measurement.
Published evidence highlights several mechanical and physiologic limitations of robot‑assisted gait training (RAGT), including abnormal sensory stimuli from straps, reduced muscle activation, passively induced movements, limited trunk/pelvis movement, and altered foot pressure patterns. These device‑ and technique‑related limitations may reduce the ability of RAGT to produce normal gait patterns or expected functional gains in some spinal cord injury and other patient populations.
Available guideline and review sources do not list robotic‑assisted rehabilitation among recommended management options for proximal or midshaft humeral fractures. UpToDate reviews cited in the policy on proximal and midshaft humeral fractures do not mention robotic‑assisted rehabilitation, implying a lack of guideline endorsement for this indication.
This Clinical Policy Bulletin provides a partial, general description of Aetna plan benefits and is intended to assist in administering benefits; it does not guarantee coverage. The bulletin is not a contract or medical advice, and coverage determinations remain subject to individual plan terms and documented medical necessity.
Robotic‑assisted gait training for chronic or ambulatory patients has shown limited and inconsistent evidence of superiority over equivalent‑dose conventional over‑ground training. Systematic reviews and RCT summaries report no reliable advantage for routine use in chronic or ambulatory populations; therefore routine authorization for such patients should be supported by individualized evidence of likely benefit and objective outcome measures.
In a large multicenter randomized trial of 770 participants the robot‑assisted upper‑limb program did not improve upper‑limb functional recovery (ARAT success) compared with usual care or an enhanced upper‑limb therapy (EULT) program, and economic evaluation found robot‑assisted training to be the most costly option with low probability of cost‑effectiveness at typical WTP thresholds. Given these findings, robot‑assisted training as delivered in that trial did not demonstrate added functional benefit or favorable value compared with usual care.
Pooled evidence indicates that RAGT and BWSTT provided solely to increase walking speed or distance do not reliably outperform comparable over‑ground gait training. Meta‑analyses and systematic reviews report no consistent superiority for walking speed or distance, so using RAGT/BWSTT only for marginal gains in speed/distance over conventional training is not supported by the evidence.
Protocols identical to those used in the MIT‑Manus multi‑center trial (45‑minute sessions, three times weekly for 12 weeks) did not demonstrate superiority over usual care or EULT for upper‑limb functional recovery in the trial population. Therefore, replication of that exact protocol for routine clinical coverage is not supported without evidence of individualized benefit.
The body of evidence is limited by methodological issues in multiple studies, including small sample sizes, lack of blinding, and absence of control groups in several reports. These limitations constrain confidence in effect estimates and underline the need for larger, well‑controlled randomized trials before routine coverage can be broadly endorsed.
This portion of the policy does not enumerate explicit clinical conditions that are designated 'not medically necessary.' Instead, it identifies interventions and devices considered experimental or investigational and emphasizes that coverage decisions depend on plan terms, documented medical necessity, and alignment with the available evidence.
Coding and Billing References
| L8701 | Powered upper extremity range of motion assist device, elbow, wrist, hand with single or double upright(s), includes microprocessor, sensors, all components and accessories, custom fabricated. |
| L8702 | Powered upper extremity range of motion assist device, elbow, wrist, hand, finger, single or double upright(s), includes microprocessor, sensors, all components and accessories, custom fabricated. |
| G20 - G21.9 | Parkinson's disease. |
| G35 | Multiple sclerosis. |
| G70.00 - G70.9 | Myasthenia gravis and other myoneural disorders. |
| G73.1 - G73.3 | Other specified myoneural disorders. |
| G80.0 - G80.2 G80.4 - G80.9 | Cerebral Palsy. |
| I69.031 - I69.069 I69.131 - I69.169 I69.231 - I69.269 I69.331 - I69.369 I69.831 - I69.869 I69.931 - I69.969 | Sequelae of cerebrovascular disease, monoplegia, hemiplegia and hemiparesis, and other paralytic syndrome. |
| S06.0X0A - S06.A1XS | Traumatic brain injury. |
| S14.101+ - S14.149, S14.151+ - S14.159+, S24.101+ - S24.119, S24.131+ - S24.149+, S24.151+ - S24.159+, S34.101+ - S34.119+, S34.121+ - S34.129+, S34.131+, S34.132, S34.139+ | Incomplete lesion of spinal cord. |
| S42.201A - S42.296S | Fracture of upper end of humerus. |
Provider Actions, Prior Authorization, and Documentation
PA: alignment with evidence (gait training)
Prior authorization: Electromechanical-assisted gait training (including robotic-assisted gait training, Lokomat, and similar devices) is most supported when provided in combination with physiotherapy and structured gait-training programs. Prior authorization should require documentation that the intervention will be delivered as part of a combined physiotherapy program (not as a standalone modality).
- Require description of planned combined physiotherapy and device-based sessions (frequency, duration, therapy type).
- PA should note patient’s ambulatory status and timing relative to stroke onset (acute/non-ambulatory patients derive most benefit).
Structured program documentation for IDEO
When Intrepid Dynamic Exoskeletal Orthosis (IDEO) or similar integrated orthotic-and-rehabilitation programs are used, prior authorization or documentation should include enrollment in a structured, integrated program (for example, 'Return to Run') and evidence of participation in the specified protocol.
- Provide program name, start date, expected duration, and therapy schedule.
- Include baseline and interim functional testing as part of the program.
Objective measures, treatment dose and participation required
Prior authorization and clinical documentation should include objective baseline measures, planned treatment dose, and intended outcome measures. Submission of these elements is required for review.
- Baseline measures: neurologic level, functional status (WISCI, FAC, SCIM, AIS, NIHSS, ARAT, FM-UE, DASH, WMFT-O as applicable).
- Planned treatment dose: total number of sessions, duration per session, therapy frequency, total training hours (note: many studies identify >15 hours as associated with measurable UL effects).
- Planned outcome measures and timing of follow-up assessments.
Prior authorization not specified
No explicit prior authorization requirements are specified elsewhere in this document segment for some devices and indications. Providers should follow local plan rules; absence of an explicit PA requirement in this bulletin does not guarantee coverage.
- Check member-specific benefit plan for PA rules and coverage exclusions (e.g., exercise equipment exclusions for MyoPro).
Experimental and Investigational indications
Robotic-assisted rehabilitation for the upper and lower limb is considered experimental and investigational for listed indications due to insufficient evidence of effectiveness. Coverage is not supported for these indications unless plan language allows or additional evidence is provided.
- Noted indications: humeral fracture; incomplete spinal cord injury; neuromuscular diseases (cerebral palsy, multiple sclerosis, Parkinson disease); stroke; traumatic brain injury.
- Specific devices labeled investigational: IDEO, Myomo e100, Myomo MyoPro, powered hip orthoses.
Risk from deviation from studied protocols
Providing electromechanical-assisted gait training outside the combined physiotherapy protocols evaluated in trials may not achieve the same benefits seen in studies. Risk of providing therapy that deviates from studied protocols should be considered when authorizing or billing.
- Document how planned intervention adheres to the protocols (session length, combined PT content) used in supporting studies.
- If deviation is planned, provide rationale and supporting evidence.
Cost-effectiveness may affect coverage
Cost-effectiveness findings from large RCTs and health economic analyses may affect coverage decisions. Interventions that are not cost-effective at common willingness-to-pay thresholds may be subject to limitation or denial.
- Document expected resource use and alternative lower-cost therapy options.
- Be aware that robot-assisted training was not cost-effective compared with usual care or EULT in cited trials.
Insufficient evidence for pediatric RAGT
Evidence for pediatric robotic-assisted gait training (RAGT) is limited and inconsistent, particularly outside cerebral palsy. Insufficient evidence for pediatric RAGT may lead to denial if medical necessity is not clearly established.
- If used in children, submit pediatric-specific outcomes, monitoring plans, and adverse event surveillance.
- Identify diagnosis-specific evidence supporting the proposed RAGT use.
Lack of demonstrated benefit in RCT
A large multicenter RCT did not demonstrate improved upper limb functional recovery with robot-assisted training versus usual care or enhanced upper limb therapy (EULT); robot-assisted training was not cost-effective. These findings support careful authorization and documentation requirements.
- For upper limb robot-assisted programs, require justification showing how proposed use differs from programs evaluated in the RCT or how it will address identified limitations.
- Include plans to measure clinically meaningful functional outcomes (ARAT, FM-UE, ADL measures).
None specified in this excerpt
No additional provider-action items are specified in this excerpt beyond the documentation, PA alignment with evidence, and investigational listings noted above.
- Follow plan-specific medical necessity and PA rules for device-based rehabilitation.
Administrative disclaimer
Administrative: Clinical Policy Bulletins are intended to assist in administering plan benefits and are not guarantees of coverage. Providers must confirm member-specific benefits and follow plan procedures for prior authorization and claims submission.
- Clinical Policy Bulletins provide partial descriptions of benefits and do not constitute a contract.
- Providers remain responsible for medical advice and treatment; verify coverage and PA requirements with the payer.
Suggested supporting documentation
Suggested supporting documentation: Include device-specific justification, objective baseline and planned outcome measures, and evidence that the intervention is part of a structured therapeutic program when applicable.
- Device description and FDA status (clearance/510(k) vs. exercise equipment designation).
- Rationale linking device use to specific deficits and expected functional gains.
Required clinical documentation elements
Required clinical documentation elements: Document baseline neurologic level, functional status measures (WISCI, FAC, SCIM, AIS, NIHSS, ARAT, FM-UE, DASH, WMFT-O), cognition, pain, gait speed, and ADL status as applicable.
- Provide dates and scores for baseline assessments and planned follow-up timepoints.
- If trial protocol exists, submit the protocol and intended follow-up schedule.
Outcome and cost documentation
Outcome and cost documentation: Trials demonstrated limited translation of impairment gains into functional improvement and higher costs for robot-assisted training. Providers should document anticipated outcomes and expected resource use.
- Include projected functional endpoints (e.g., ARAT improvement, walking speed, 6MWT) and cost estimates for the proposed program.
- Report prior therapies and response to date to show incremental benefit expected from the device-based intervention.
Outcome measure and AE documentation
Outcome measures and adverse event (AE) documentation should be included with any authorization or claims: report baseline and post-intervention measures (standing ability, 6MWT, TUG, ARAT, FM-UE, DASH, WMFT-O), and document any AEs.
- Specify timing of post-intervention assessments and define criteria for clinical success.
- List any device-related AEs and serious AEs, and indicate attribution to intervention.
Required clinical outcome documentation
Required clinical outcome documentation for upper limb robotic trials commonly includes DASH, WMFT-O, ROM, pain scales, cognition assessments, and ARAT/FM-UE. Ensure these are included when relevant.
- Provide numeric scores and change from baseline for each outcome measure at defined follow-up points.
- If long-term follow-up is planned, provide schedule and method (in-person, postal, or phone).
Study protocols and clinical follow-up
Study protocols and clinical follow-up: Trials frequently included baseline assessments (cognition, pain, ability to work, gait speed, ARAT, DASH, ROM, WMFT-O) and predefined follow-up timepoints (post-intervention, 3 months, 6 months, 12 months). Provide equivalent follow-up plans when requesting authorization.
- Specify baseline and follow-up assessments, measurement tools, and timing.
- Indicate who will conduct assessments (blinded assessor when feasible).
Policy bulletin use
Policy bulletin use: Clinical Policy Bulletins assist in administering plan benefits and provide partial descriptions; they do not guarantee coverage. Verify member-specific benefits and plan rules.
- This bulletin does not constitute a contract or coverage guarantee.
- Providers must follow payer-specific PA and claims processes.
Prior conventional therapy and step therapy preference
Prior conventional therapy and step therapy recommendations: Evidence suggests therapist-assisted locomotor training or progressive over-ground training (OGT) may be as effective or superior to robotic-assisted approaches for some outcomes. Consider requiring a trial of conventional therapy or equivalent-intensity upper-limb therapy (EULT) before approving robotic-assisted programs.
- Require documentation of prior conventional gait or upper-limb therapy (dates, frequency, objective response) unless contraindicated or not feasible.
- If step therapy is not required by plan, note that evidence supports RAGT as adjunctive rather than first-line replacement therapy.
Conventional therapy prior to RAGT; RAGT as adjunctive therapy
Conventional therapy prior to RAGT and RAGT as adjunctive therapy: Given mixed evidence, RAGT should generally be considered adjunctive to multi-modal rehabilitation rather than a substitute for conventional therapies.
- Document concurrent rehabilitation modalities and therapist involvement (percent of session with active therapist input).
- Describe how RAGT will be integrated into the overall rehabilitation plan.
No step therapy requirements are described
No routine step therapy requirements are described in this bulletin; however, payers may implement step-wise requirements per plan. Providers should confirm if step therapy (conventional therapy trial) is required prior to authorization.
- If no step therapy is in force, still provide documentation of prior therapy and rationale for proceeding to device-based rehabilitation.
Background and Evidence Overview
Stroke is a leading cause of long‑term disability; more than half of patients with post‑stroke upper‑limb paresis have persistent arm impairment. This clinical context underlies consideration of robotic and myoelectric devices as potential aids for rehabilitation, while also noting that current evidence for many robotic interventions remains mixed or preliminary.
Definitions and Device Descriptions
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.